Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer (TC) and accounts for approximately 10% of all TC cases. Liver metastases are a rare presentation in 0.5-1% of follicular thyroid cancers, usually occurring in the setting of widely disseminated FTC disease, and their presence is associated with poor prognosis. Until now, there have been only 30 cases of FTC liver metastases described in the literature. Herein, we review publications and describe diagnostic tools that may be used in the diagnosis and follow-up of FTC metastases to the liver, including biopsy and imaging techniques like US, CT, MRI, SPECT, PET, and radioiodine scintigraphy. We also present and discuss current methods of treatment, e.g. TSH suppressive therapy with levothyroxine, surgery, radiofrequency ablation (RFA), transarterial embolisation (TAE), liver transarterial chemoembolisation (TACE), chemotherapy with cisplatin and doxorubicin, treatment with Indium-111-octreotide (or its analogues), and tyrosine kinase inhibitors (sorafenib, sunitinib). At the end we describe the course, results of diagnostics, and treatment in a patient with large multiple FTC metastases to the liver. 
Introduction
Follicular thyroid carcinoma (FTC) accounts for up to 10% of all thyroid malignancies in iodine-sufficient regions of the world. In iodine-deficient areas the prevalence of FTC is higher it accounts for up to 25-40% of thyroid malignancies [1, 2] . FTC tends to occur between the fourth and the sixth decade of the patient's life, later than in the case of PTC (between the third and fifth decade of life) [3] . Female predominance in FTC is observed with a female-to-male ratio of 3:1. Follicular cancer has a tendency to be more aggressive than PTC and is more often diagnosed as a larger tumour with distant metastases at initial diagnosis [4, 5] .
In contrast with PTC, FTC usually metastasises via haematogenous dissemination, although visceral
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metastases from FTC are very rare and occur in 10 to 15% of patients at initial presentation [6] . Tumours less than 2 cm in diameter are usually not associated with metastatic spread [6] . FTC metastasises mostly to the bone and lungs. Rare sites of FTC metastases include the patient's brain, kidneys, bladder, liver, breasts, and skin [4, 7] . The rate of liver metastases from DTCs is in general about 0.5%, but in autopsy involvement of the liver was reported to be in about 25% of FTC patients [8] [9] [10] [11] .
Until now 30 cases of liver metastases from FTC (Table I ) have been described in literature. The reported frequency of isolated metastases to the liver from DTC is below 1.0% [11, 12] . When liver metastasis occurs, metastatic disease usually involves multiple sites including lung, bone, and brain [13] [14] [15] [16] [17] [18] [19] [20] .
The time elapsed between the diagnosis of the thyroid cancer and the expression of the metastases ranges from the moment of initial thyroid cancer diagnosis to 32 years, in the literature [20, 21] .
Well-differentiated FTC results in small functionality of its metastases, high iodine uptake, and production of thyroglobulin [8, 20, 21] . Thyrotoxicosis in the case of FTC metastases is usually the result of large volume multiple metastases, often involving bones [22, 23] . It is observed more often in iodine-deficient regions. Thyrotoxicosis was described only in few cases of FTC with liver metastases by Guglielmi et al. and Kondo et al. [18, 19] .
Liver biopsy and imaging study in FTC metastases
Liver tumours are usually detected incidentally by US and/or CT. Liver fine needle aspiration biopsy (FNAB) and core biopsy are valuable tools in establishing NA -not analysed; TKI -tyrosine kinase inhibitor; RFA -radiofrequency ablation
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a definitive diagnosis of focal liver masses in suspected metastatic liver disease [24] . According to the latest American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) guidelines, in liver lesions greater than 2 cm, non-invasive diagnostic strategies based on computed tomography (CT) and magnetic resonance imaging (MRI) should be followed with liver biopsy. Liver biopsy can give false negative results even with use of immunohistochemical techniques [25] . The rate of false negative results reaches up to 30% [26] . If the lesion grows or imaging patterns vary, a second biopsy is recommended [27] .
Percutaneous FNAB of abdominal lesions guided by imaging methods has been used in diagnostics for over 30 years [28] . Fine needle aspiration biopsy has sensitivity greater than 85% and specificity as high as 100% [28, 29] . Data on biopsy of DTC hepatic metastases are very limited. Follicular cancer metastasis can mimic cytologically hepatocellular cancer [30] .
PostterapeuticaI-131-whole body scan (WBS) and I-131 single photon emission computed tomography (I-131-SPECT-CT) are useful in anatomic and metabolic assessment of the lesion. High uptake of I-131 in the liver and radioactivity in the gastrointestinal tract even for many hours after the dose make it hard to distinguish between areas with pathological or physiological uptake of radioiodine. Careful evaluation of the liver on the scans to distinguish between diffuse and focal radioiodine accumulation in liver is essential. A focal accumulation is typical for functional liver metastasis with preserved thyroxin synthesis [15] . FTC tumours are usually well differentiated, but liver masses are usually I-131 negative, which can indicate dedifferentiation of FTC. Functional (accumulating radioiodine) hepatic metastases from DTC are rare [11, 31, 32] . False positive findings of focal hepatic uptake in postterapeuticI-131-WBS have been described in the literature, e.g. in the case of liver abscess [33] . Stokkel et al. have reported a high diagnostic value of Indium-111-octreotide scintigraphy in patients with DTC metastatic disease and negative I-131-WBS that does not respond to RAI treatment. Whole body scan after radioactive iodine (RAI) treatment could be a precise and sensitive tool for detecting functioning metastases [34] . Diffuse liver uptake on I-131 whole-body scans is related to the quantity of administrated I-131-dose and the ability to uptake radioactive iodine (RAID) [32] . Focal tracer uptake is typically seen in functional hepatic metastases from DTC whereas diffuse hepatic uptake has been reported also in patients after RAI therapy [31, 32, 35, 36] . Diffuse liver uptake could be associated with the presence of functioning residual thyroid or metastatic lesions in other sites [37] .
The liver is an important organ in the metabolism of thyroid hormones, responsible for concentration of thyroxine (T4), in 40% of its deiodination and in 70% of production of triiodothyronine (T3) [38] . Hepatic accumulation of radiolabeled thyroid hormones is present in patients with metastases, when thyroglobulin (Tg) is released from functioning tumour tissue and then metabolised and absorbed by the liver. Thyroid hormone status, medications, stress, infection, and severe concomitant diseases may change thyroxine metabolism and liver uptake. Also unspecific serum iodinated proteins may be responsible for liver visualisation [32, 37] .
The predominance of the significant diagnostic value of SPECT-CT over planar imaging is invaluable.
Results of SPECT-CT may modify management in as many as 25-50% of patients [39, 40] . The sensitivity of SPECT/CT for identification of iodine uptake in the lungs, liver, and bone is significantly better than that by planar scanning in postsurgical patients, helping to avoid additional imaging methods and to change the management and implication for follow-up if needed [41] .
In the case of low or complete lack of radioiodine uptake, 18F-fludrodeoxyglucose-positron emission tomography (FDG-PET) is recommended due to its diagnostic and prognostic impact. PET constitutes an expensive but effectual instrument in restaging DTC patients with metastatic disease to groups of low (18F-fluoro-2-deoxyglucose (FDG negative) and high risk (FDG positive) of thyroid cancer mortality [42] . Age over 45 years during PET examination, SUV max, distant metastatic processes, and volume of FDG-avid disease emerged as strong survival predictors [43] . In a study by Robbins et al., only initial PET scan was considered, but probably a series of FDG scans could provide a better follow-up of the disease. In the same study, the influence of TSH on FDG retention was not shown, but some other reports found that kind of dependence [44] . Hong et al. also found an inverse relationship between the presence of FDG uptake, maximum standardised uptake value (SUV max), and survival of individuals with DTC [45] . Scintigraphy and PET remain the imaging methods to determine the functional status of thyroid cancer metastases.
Treatment of FTC with distant metastases
Proper treatment of metastasis disease is crucial for further life-prognosis. If possible, excision of the metastatic lesion, TSH suppression therapy with L-thyroxine, and I-131 therapy if metastases concentrate radioiodine is pivotal.
RAI therapy is administrated for remnants ablation after surgery and as an adjuvant therapy. FTC metastases concentrate I-131 in 75% of patients [46] . In case
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of distant metastases, especially those larger than 1 cm in size and localised in bone, RAI therapy is claimed to be less effective [47] . Solitary, resectable liver metastasis from DTC are present extremely rarely. An isolated liver metastasis from DTC should be considered for surgical resection -anatomic segmental resection, which gives a better chance for longer survival [17, 48] .
Radiofrequency ablation (RFA) is implemented for various types of liver tumours, also in palliative treatment of liver metastases from thyroid carcinoma to release symptoms [49] . The ablation could be performed via laparotomy or percutaneously. RFA should be taken into account as a cytoreductive modality increasing the effectiveness of RAI treatment (in RAI-avid metastases), but also in patients with no or low RAI uptake [49, 50] . In lesions larger than 5 cm, RFA is reported to be less effective [49] . There are two documented cases of RFA for liver metastases from medullary thyroid carcinoma and one from FTC [18, 49] . Local recurrences of the ablated liver metastases have not been observed during follow-up [49] . RAI effectiveness and safety could be improved by initial percutaneous interstitial laser photocoagulation in cases of hyperfunctioning and unresectable liver metastases from DTC [18] .
Transarterial embolisation (TAE) is an additional option for the management of liver metastasis [51, 52] . TAE is a tool used successfully in the treatment of hepatocellular cancer and liver metastasis from gastrointestinal tract, neuroendocrine tumours, etc. [53] [54] [55] . One example of TEA treatment combined with RFA and RAI in a patient with FTC and liver metastases with survival of only six months was described [49] .
Positive reports on liver transarterial chemoembolisation (TACE), combination of TEA and chemotherapy in hepatic metastases only from medullary thyroid cancer (MTC) with partial radiological tumour response up to 42%, and stabilisation of liver metastases up to 42-60% were published [56, 57] .
Chemotherapy with cisplatin and doxorubicin is another treatment modality in metastases that are refractory to RAI and unresectable [58] .
In patients with metastatic DTC disease that does not respond to treatment with high-dose I-131, treatment with Indium-111-octreotide or its analogues is another opportunity [59] .
The therapy with tyrosine kinase inhibitors (TKI) holds high expectations in the treatment of thyroid metastases. The ability of sorafenib to inhibit angiogenesis and to block several protein kinases, especially BRAF-1, RET, VEGFR, PDGFRA, and c-KIT led to several phase II and III studies including DTC patients [60, 61] . Sorafenib in the form of oral tablets was permitted by the U.S. Food and Drug Administration (FDA) for use in the treatment of late-stage metastatic DTC in 2013. The effectiveness of sorafenib in DTC differs depending on the trial, and partial response (PR) rate ranges from 6% to 49% [62] . In a recent large trial progressive-free survival (PFS) reached 10.8% in I-131-resistant DTCs (compared to PFS 5.8% in a placebo group) [63] . Skin rash, diarrhoea, and hand and foot syndrome are the most common side effects of sorafenib [60] [61] [62] [63] [64] .
Six patients with DTC and metastases to the liver were treated with tyrosine kinase inhibitors (sorafenib, sunitinib) out of clinical trials and were included in a retrospective study of TUTHYREF network. Lung (with a median tumour response of 22%) and hepatic lesions (with a median tumour response of 18%) were the most reactive DTC metastases to the treatment, although bone and pleural metastases were the most recalcitrant ones. DTC patients' median PFS on sorafenib ranged from 7.2-19.8 months in previous studies [60, 61, 63, 65] . Brient et al. described eight more patients with DTC (including four cases of FTC) and concomitant liver metastases treated with TKI. In their work the median survival after diagnosis of liver metastasis from DTC was significantly longer in patients who were put on TKI treatment compared with patients who did not received any specific therapy (23.6 vs. 3.9 months, p < 0.001). In this study, patients with bilobar liver involvement were excluded [66] . The mechanism of development of the resistance of DTC to TKI is currently being studied and could be the reason for metastases' dormancy [67] . To conclude, sorafenib activity was tested in a relatively small group of patients with DTC liver metastases and its efficiency in FTC not I-131 avid liver metastases is not well documented.
Prognosis in FTC patients with distant metastases
Although FTC tends to have an excellent prognosis, the presence of metastatic disease results in a bad prognosis [68] . In a large study by Hundahl et al. a 10-year relative survival rate of 85% for FTC and 15% cancer-mortality rate were found [69] , and a 20-year cancer-specific survival rate of 73.7% for all FTCs was recognised by Verburg et al. [5] . In FTC patients without distant metastatic disease 20-year disease-specific mortality rates reached 80.2%, which was significantly lower than that for non-metastatic PTC (93.1%) [5] . In PTC and FTC patients with distant metastatic disease, there no significant difference in 20-year disease-specific mortality in Cox regression was observed [5, 70] .
DTC liver metastases prognosis is poor, according to previously described cases [11] . Apart from the site of metastasis, there are a few other characteristics that were found to be prognostic factors. Age over 45 years
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and multiple organ involvement are both independent factors of thyroid cancer mortality [71] . Typically, patients over the age of 40 have a more aggressive disease and are less likely to respond to radioiodine therapy [7, 72] . According to the literature, women may have a better prognosis than men [7] . The impact of iodine supplementation on mortality from FTC is not clear [73] . DTC accompanied by distant metastasis at initial diagnosis seems to have auspicious outcomes as compared with DTC patients who develop distant metastasis after primary treatment [74] . Metastases iodine avidity has an important impact on the disease-specific survival (DSS) rate [74] . Individuals with radioactive iodine avid and responsive DTC metastases are characterised by a 10-year survival rate of 90%, whereas patients with radioiodine non-avid and refractory DTC metastatic tumours have a 10-year survival rate of about 10% [50] . Although Robbins et al. found that patients with concentration of I-131 on scans had significantly poorer survival, compared with the rest, which can be the result of overlooking disease evidence in that specific group of patients [42] . In another study by Hong et al., RAI -in metastatic lesions correlated with reduced cancer-specific survival [75] .
As mentioned above, according to several reports no 18F-FDG activity in the distant metastases of DTC is prognostically favourable [42, 75, 76] . In the postoperative evaluation of DTC, FDG-PET is a sensitive tool to diagnose metastases, but negative PET does not exclude the presence of non-functional, FDG-negative metastatic lesions. FDG-PET findings correlate with the stage of the disease, progression-free survival (PFS), and long-term outcome [42, 76, 77] . FDG PET, conducted even before thyroidectomy, is postulated to be a highly valuable predictor for long-term survival in high-risk patients with DTC [78] .
Conclusions
Due to the risk of recurrence and emergence of metastases, careful surveillance of the patients with FTC should be performed routinely. Methods of evaluation for the presence of distant metastases besides thyroglobulin level should also include sensitive imaging techniques. Ultrasound imaging, 131-I WBS, and SPECT-CT constitute the standard methods in the management of patients with DTC. CT and PET are supporting methods of high diagnostic value, especially in cases of non-avid metastases in I-131 scans. Both SPECT-CT and PET-CT present high diagnostic performance in detecting metastatic spread in thyroid cancer. FDG-PET may fail to identify all DTC metastases. CT in combination with biopsy may be a better, cheaper diagnostic tool, although PET seems to be valuable instrument in the prediction process.
Once distant metastatic disease is diagnosed in DTC patients, FDG-PET helps to identify high-and low-risk individuals.
Because of the rarity of patients with metastases of FTC to the liver, prognosis and follow-up data are limited. Establishing algorithms of dealing with rare visceral metastases from DTC, especially unresectable ones, is necessary. Collecting more data on rare DTC metastases should allow the best outcomes in the diagnosis and treatment of patients with this rare metastases localisation.
Patient with liver metastases of FTC -case report
A 67-year-old patient was referred to the Endocrinology Outpatient Department in February 2013 because of a history of hyperthyroidism, treated with radioiodine administered twice approximately 20 years ago. Additionally, the patient had been treated for hypertension and had complained of recurrent laryngeal and bronchial infections. The patient had no history of diabetes, cardiac, pulmonary, or renal disease.
The ultrasound examination of the thyroid gland revealed a nodule in the right lobe, 20 × 20 mm in size. Fine-needle aspiration biopsy (FNAB) of the lesion was performed. The cytology results disclosed carcinoma cells, probably papillary thyroid carcinoma (PTC). At that time the patient was euthyroid. The patient was referred to the surgical ward for total thyroidectomy. In April 2013 total thyroidectomy with central lymphadenectomy was conducted. The final histopathology diagnosis was follicular thyroid cancer, pT2N0 stage, with microinvasion of the vessels (maximal diameter of the tumour 21 mm, immunohistochemistry results: calcitonin -negative; thyroglobulin -positive) (Fig. 1A-C) . In September 2013 the patient was admitted to the Endocrinology Department for diagnostics and ablative radioiodine treatment (RIT). The patient received 142 mCi (5.3 GBq) of radioiodine (I-131) under endogenous TSH stimulation (thyroglobulin (Tg) > 1000 ng/mL, antithyroglobulin antibodies (aTg) > 4000 IU/mL). The chest X-ray was normal. Thyroid ultrasound revealed small remnants of both thyroid lobes. A whole body scan after radioiodine treatment (Infinia Hawkeye Gamma Camera; GE Healthcare) showed only bifocal uptake in the thyroid bed and nonspecific diffuse liver uptake. In an additionally performed SPECT-CT only degenerative joint disease (arthritis) in the spine was additionally exposed. Subsequently, the patient received a suppressive dose of levothyroxine (LT4).
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The patient came to a general practitioner (GP) in December 2013 due to abdominal pain. The laboratory tests showed slightly increased ECR (19 mm, normal range < 16 mm) and gamma-glutamyl transpeptidase (GGTP) -73 U/L (normal range < 40 U/L), with bilirubin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), and asparagine aminotransferase (AST) within normal range. Abdominal ultrasound revealed a significantly enlarged liver with heterogeneous echogenicity. The right liver lobe was completely filled with a solid mass of polymorphic structure with blurred margins. In the left liver lobe a solid lesion of about 90 × 80 mm and a cyst of size 23 mm were found.
The patient was referred to the Greater Poland Cancer Centre for further diagnostics, where computed tomography colonography (CTC) was performed. The examination showed no colonic pathology. At the same time, multiple hepatic masses were diagnosed: two large tumours with dimensions: 100 mm (segment 3) and 145 mm (segment 5/6) and four smaller liver lesions of size: 30 mm (segment 2/3), 17 mm (segment 7), 14 mm (segment 4), and 12 mm (segment 1). These lesions were interpreted as massive metastases or hepatocellular cancer. Additionally, lipid-rich adenoma of the left adrenal gland (18 mm in size) as well as a subpleural nodule (7 mm) in the left lung was found. Tumour marker levels (CEA, alpha-fetoprotein, CA-125, CA-15.3, CA-19.9) were within normal ranges. FNAB of the liver under computed tomography (CT) control was performed two days after the CT colonography. The cytological result based on cell morphology and immunohistochemistry stainings: Ki-67 1% positive tumour nuclei, thyreoglobulin(+), TTF-1(+), HEPPAR(-), cytokeratin 7(+/-), cytokeratin 19(-), CEAp(-), AFP(-), and CD34(-), confirmed the presence of follicular thyroid cancer metastases (Fig. 1D, 1E, 1F) .
In February 2014 the patient returned to the Endocrinology Department for an imaging control and biochemical study. The patient reported discomfort in the abdomen and bloating. Tg level was above 50,000 ng/mL, anti-Tg antibodies level was 2721 IU/mL (normal range < 60 IU/mL). In chest CT small nodules in both lungs, up to 8 mm diameter, of uncertain origin, were described. In abdominal CT three large liver tumours were found (diameters: 93 mm, 153 mm, and 17 mm) and multiple smaller tumours.
A PET/CT scan (PET/CT scanner Discovery ST, GE Healthcare) performed in February 2014 showed two large hepatic masses with only slight accumulation of 18F-FDG on the periphery (SUVmax = 2.9 vs. 2.4 in the normal liver parenchyma) ( Fig. 2A, 2B) . Two pulmonary nodules of 5 mm and 7 mm in diameter were visualised as well. No tracer uptake in these nodules was observed (the metastatic character could not be excluded). In the left adrenal gland a nodule of 16 mm was disclosed showing no 18F-FDG accumulation, interpreted as a benign lesion.
Figure 1. (A, B) encapsulated primary tumor mass invading a capsule (HE, 20×); (C) primary tumor spread to a vessel in a capsule (HE, 40×); (D) secondary tumor, metastasis to the liver, cytological morphology details shows possible follicular thyroid cancer origin of the tumor (HE, 40×); immunohistochemistry evaluation confirms the type of differentiation; (E) metastasis to the liver, thyroglobulin (+) cytoplasmic reaction; (F) metastasis to the liver, TTF1 (+) nuclear reaction. The other performed immunohistochemistry reactions Cytokeratin 7 (+/-), Cytokeratin 19 (-), HEPPAR (-), CEA (-), AFP (-) are not shown
A B C D E F
SZKOLENIE PODYPLOMOWE
(VCI) was reported, without signs of thrombosis in Doppler ultrasound examination. Because of the progression of FTC metastatic disease and no marked radioiodine-avidity of the lesions, liver transplantation was considered, but due to the patient's age (over 65 years old) and a high risk of cancer recurrence within one year of immunosuppression, this type of treatment was contra-indicated. Instead, the sorafenib treatment was initiated (Nexavar, in a dose of 800 mg per day) in December 2014. The patient has been under careful observation until now. The patient received 144 mCi (5.3 GBq) of radioiodine in May 2014 under recombinant human TSH (rhTSH, Thyrogen, Genzyme) stimulation. Postradioactive iodine therapy (post-RAI) scan revealed moderately avid diffuse liver uptake with moderate accumulation of tracer in the lower part of the right lobe of the liver (Fig. 3) .
The follow-up abdominal CT in August 2014 showed a progression of metastases in the liver (113 × 92 mm and 35 mm in segment 2/3, 190 × 130 × 190 mm in the right lobe) (Fig. 4) . Compression of vena cava inferior A B
dobrze zróżnicowane, jednakże przerzuty do wątroby przeważnie nie wychwytują jodu promieniotwórczego. Wskazywać to może na odróżnicowywanie się nowotworu w przypadku powstawania tych przerzutów. Funkcjonalne (wychwytujące radiojod) przerzuty do wątroby z raka pęcherzykowego tarczycy są rzadkie [8, 31, 32] . Fałszywie pozytywne ogniskowe gromadzenie znacznika w obrębie wątroby stwierdzane w scyntygrafiach poterapeutycznych było opisywane w literaturze, na przykład w przypadku ropni wątroby [33] . Stokkel i wsp. opisywali dużą wartość diagnostyczną scyntygrafii z In-11-oktreotydem u pacjentów z rozsianym rakiem zróżnicowanym tarczycy i negatywnymi scyntygrafiami po terapii 131-I, którzy nie odpowiadali na leczenie radiojodem [34] . Scyntygrafia poterapuetyczna po leczeniu jodem promieniotwórczym może stanowić precyzyjne i czułe narzędzie do poszukiwania przerzutów funkcjonalnych [34] . Rozlany wychwyt w wątrobie widoczny w scyntygrafiach całego ciała jest zależny od ilości podanego radiojodu oraz zdolności wątroby do jego wychwytu [32] . Ogniskowy wychwyt znacznika jest typowo obserwowany w funkcjonalnych przerzutach raka zróżnicowanego tarczycy do wątroby, podczas gdy rozlany wątrobowy wychwyt był opisywany nawet u 44% pacjentów bez przerzutów do wątroby po terapii radiojodem [31, 32, 35, 36, 37] . Wątroba jest ważnym organem metabolizującym hormony tarczycy, reguluje stężenie tyroksyny (T4), 
